Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Total revenues	$ 117,029	$ 257,178
Cost of revenues	(117,029)	(226,040)
Gross profit		31,138
Operating expenses:
Research and development	1,095,040	946,451
General and administrative	1,022,051	1,235,376
Total operating expenses	2,117,091	2,181,827
Loss from operations	(2,117,091)	(2,150,689)
Other income (expense):
Foreign currency transaction gain (loss)	1,209	(366)
Interest income (expense), net	28,842	(103,568)
Research and development incentives	6,331	6,448
Other income		40,869
Change in fair value of convertible debt	165,382
Total other income (expense)	201,764	(56,617)
Net loss before income taxes	(1,915,327)	(2,207,306)
Income tax benefit		1,161,197
Net loss applicable to common stockholders	$ (1,915,327)	$ (1,046,109)
Basic net loss per share (in Dollars per share)	$ (0.18)	$ (0.36)
Diluted net loss per share (in Dollars per share)	$ (0.18)	$ (0.36)
Basic weighted average common shares outstanding (in Shares)	10,521,233	2,914,929
Diluted weighted average common shares outstanding (in Shares)	10,521,233	2,914,929
Grant revenue
Total revenues	$ 117,029	$ 257,178